Enterprise Value
24.15M
Cash
50.43M
Avg Qtr Burn
-276.3K
Short % of Float
1.72%
Insider Ownership
9.25%
Institutional Own.
33.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
REZZAYO (Rezafungin) Details Infectious disease, Fungal infections, Candidemia | Approved Quarterly sales | |
Rezafungin Details Infectious disease, Fungal infections | Phase 3 Update | |
CD388 (DFCs) Details Infectious disease, Influenza | Phase 2a Data readout |